Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 21 · below the Ichimoku cloud · RSI 15 (oversold) · MACD above its signal
None of the 29 investors followed here reported a position in GRRMF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GRRMF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for GRRMF.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | -61.0 | 9.8 | -6.1 | 55.9 | -4.6 | 3.1 | 1.6 | -9.8 | 0.0 | −43.5% | ||
| 2025 | -13.4 | 15.2 | -27.4 | -3.3 | -0.7 | 0.0 | 0.0 | 0.0 | 0.0 | −30.5% | |||
| 2024 | — | ||||||||||||
| 2023 | 12.1 | 0.0 | 0.0 | 32.2 | 0.0 | 0.0 | 25.3 | 7.7 | 0.0 | 0.0 | +100.0% | ||
| 2022 | -4.0 | -18.0 | -5.1 | 0.0 | -8.8 | 15.3 | -17.3 | -2.1 | -20.9 | 24.7 | 3.3 | 4.8 | −32.1% |
| 2021 | 0.0 | 0.0 | 0.0 | 0.1 | 2.8 | 0.0 | -6.2 | 0.1 | 0.0 | 0.0 | 0.0 | -7.3 | −10.5% |
| 2020 | -4.7 | 8.5 | -2.7 | 2.4 | 2.3 | 0.0 | 43.0 | 3.4 | -4.4 | -7.4 | 14.2 | -9.5 | +42.7% |
| 2019 | 0.0 | 0.0 | 0.0 | 0.0 | 17.4 | -2.3 | -1.6 | 0.0 | 0.0 | 4.7 | -2.0 | 0.0 | +15.7% |
| 2018 | 15.6 | 0.0 | -7.5 | 0.0 | 0.0 | 0.0 | 4.3 | -2.0 | 0.0 | -17.4 | 3.2 | -9.5 | −15.7% |
| 2017 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.9 | -2.2 | 0.0 | −0.3% |
| 2016 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2015 | 0.0 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.6 | 0.0 | 0.0 | 11.1 | +39.5% |
| 2014 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 1.9 | 0.0 | 6.6 | -0.8 | 0.0 | 0.0 | -22.7 | −14.0% |
| 2013 | 0.0 | 6.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 18.7 | 0.0 | 6.0 | 0.0 | +34.3% |
| 2012 | 0.0 | 0.0 | 0.0 | 0.0 | -7.0 | 6.2 | 0.0 | 0.0 | 0.0 | 8.3 | -3.9 | 0.0 | +2.8% |
| 2011 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +14.3% |
| 2010 | 0.0 | 0.0 | 2.8 | 0.0 | 0.0 | 7.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.4 | +34.0% |
| 2009 | 0.0 | 0.0 | 0.0 | 0.0% |
No analyst coverage for this instrument.
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.